In silico pharmacological evaluation of a multi-epitope vaccine candidate targeting the G1 and G2 glycoproteins of Oropouche virus via TLR3 interaction.
Findings indicate that the G1-based multi-epitope vaccine is a potential candidate for further experimental validation and may serve as an effective preventive strategy against OROV infection.